Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic endometriosis

Trial Profile

A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic endometriosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2019

At a glance

  • Drugs Vilaprisan (Primary)
  • Indications Endometriosis
  • Focus Therapeutic Use
  • Acronyms VILLENDO
  • Sponsors Bayer
  • Most Recent Events

    • 23 Jan 2019 This trial has been suspended in Sweden.
    • 08 Jan 2019 This trial has been suspended in Denmark.
    • 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top